Dear Colleagues,

This special issue aims to explore the molecular mechanisms and biomarkers associated with multiple myeloma and lymphoma—the two hematological malignancies that are prevalent worldwide. Both diseases, while distinct in their clinical presentation and therapeutic strategies, share common molecular pathways that contribute to their development, progression, and treatment resistance. Understanding these mechanisms is crucial for advancing diagnostic approaches and identifying novel therapeutic targets. The issue will highlight recent innovations in molecular biology, focusing on the genetic and epigenetic alterations that drive tumorigenesis in both multiple myeloma and lymphoma. It will also examine the role of biomarkers in disease monitoring, prognosis, and therapy selection, emphasizing their potential to guide personalized medicine. In addition, research works exploring emerging therapeutic approaches, including targeted therapies, immunotherapies such as CAR-T cells, and combination treatments, in relation to the two malignancies of interest are welcomed. The goal of this special issue is to provide a comprehensive overview of the current state of research and to identify promising directions for future studies that may lead to more effective treatments and improved patient outcomes. By bringing together cutting-edge research on molecular mechanisms, biomarkers, and innovative therapies, this special issue seeks to contribute to a deeper understanding of these complex diseases and the development of more precise, individualized treatment strategies.

Prof. Francesco Gaudio and Prof. Stefano Martinotti
Guest Editors